<DOC>
	<DOC>NCT00550446</DOC>
	<brief_summary>The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550. One out of seven will receive adalimumab (Humira®) and one out of seven will only receive inactive substances (placebo.)</brief_summary>
	<brief_title>A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subjects must have active rheumatoid arthritis Subjects must have failed at least 1 disease modifying antirheumatic drug (DMARD) Subjects must not be currently taking any DMARD other than an antimalarial Subjects who discontinued any previous TNF inhibitor therapy for either lack of benefit or safety. Subjects who previously received adalimumab (Humira®) therapy for any reason. Subjects with evidence of blood disorders, chronic infections or untreated tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Janus Kinase 3 Clinical Trial</keyword>
</DOC>